The Global Coalition for Adaptive Research (GCAR) has collaborated with Cure Brain Cancer Foundation (CBCF) to launch the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial in Australia.
The patient-centred, adaptive platform trial is intended for registration to assess multiple therapies for patients with newly diagnosed and recurrent glioblastoma (GBM), a severe brain cancer.
Adaptive randomisation is used by the study for dynamically adjusting treatments to patients.
The trial will assess multiple therapies or combinations from various pharmaceutical partners simultaneously.
Since June 2019, when enrolment began, GBM AGILE has screened more than 1700 subjects across Europe and North America.
The trial expansion to include Australian hospitals will help to increase options and access to experimental therapies for those diagnosed with GBM.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Austin Health professor Hui Gan has been selected as the regional principal investigator for Australia.
Four more locations in Adelaide, Brisbane, and Newcastle will be opening in the coming months.
GCAR CEO and president Dr Meredith Buxton said: “GCAR is committed to providing access to innovative clinical trials globally, with the hope that this will advance new treatment options to support all patients who need them.
“We celebrate the dedication and persistence of the patient and scientific community and acknowledge the resoluteness and financial support of the Cure Brain Cancer Foundation.
“Bringing GBM AGILE to Australia has been an important goal since the trial’s inception, and we thank the community’s unwavering support that has made this happen.”